Compare Novartis AG (NVS) vs iShares Semiconductor ETF (SOXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs iShares Semiconductor ETF — how do they compare? Novartis AG trades at $143.75 (market cap $268.57B), while iShares Semiconductor ETF trades at $559.4 (market cap $48.19B). The key difference: Novartis AG is far larger — about 5.6× iShares Semiconductor ETF's market cap, and Novartis AG pays a 3.31% dividend while iShares Semiconductor ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and iShares Semiconductor ETF for 46 Days on average.
| NVS | SOXX | |
|---|---|---|
Market Cap | $268.57B | $48.19B |
Volume | 1,532,573 | 10,257,578 |
Sector | Health | Sector/Thematic |
52-Week High | $168.62 | $655.01 |
52-Week Low | $121.80 | $268.10 |
Typical Hold Time | 82 Days | 46 Days |
Enterprise Value | $309.89B | — |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.11, down 0.12% with a bearish technical signal. The stock shows strong fundamentals with 24.67% net margin and $14B net income, though recent earnings were mixed with a Q1 miss. Analyst consensus is cautious with 68% hold ratings and a $146 target. Recent $7.8B licensing deal with China's Abogen highlights strategic moves amid pipeline setbacks.
Outlook remains balanced: valuation metrics appear reasonable (P/E 21.6) and profitability is robust, but clinical trial failures and investor scrutiny over M&A strategy pose risks. The stock trades near consensus target with institutional sentiment leaning neutral amid ongoing pipeline execution challenges.
SOXX trades at $563.28, down 3.37% over the past day, with a bullish technical signal from moving averages and neutral oscillators. The ETF is supported by strong AI-driven semiconductor demand, with recent news highlighting sector gains and positive earnings revisions. A 1:3 stock split is scheduled for November 2026, and a $0.33 dividend is set for September 2026.
Outlook remains positive due to robust AI infrastructure growth, though high valuations and bearish bets by investors like Michael Burry pose risks. Earnings growth is the primary catalyst, but macroeconomic factors and sector concentration could drive volatility. Wall Street sentiment is mixed, balancing long-term potential against near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About iShares Semiconductor ETF
SOXX provides investors with exposure to U.S. companies that design, manufacture, and distribute semiconductors. It tracks the ICE Semiconductor Index, offering a targeted investment in the technology sector's foundational components, including firms that produce chips, related equipment, and services. SOXX is a key vehicle for investors seeking to capitalize on trends in artificial intelligence, 5G, and other technologies that rely heavily on advanced semiconductor technology.
Read more on SOXX →
